Engineered immune cells take aim at tough lung cancer
NCT ID NCT05680922
First seen Apr 07, 2026 · Last updated May 01, 2026 · Updated 6 times
Summary
This early-stage trial tests a new treatment called LB2102, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells that have a specific marker (DLL3). The study includes about 41 adults with advanced small cell lung cancer or a related lung cancer who have already tried standard treatments. The main goals are to check the safety of this therapy and find the best dose to use in future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10017, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
University of Kentucky - Markey Cancer Center
Lexington, Kentucky, 40536, United States
Conditions
Explore the condition pages connected to this study.